Avoid common mistakes on your manuscript.
1 Correction to: Drug Safety (2021) 44:1109–1119 https://doi.org/10.1007/s40264-021-01107-6
In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Day, J.W., Mendell, J.R., Mercuri, E. et al. Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Saf 45, 191–192 (2022). https://doi.org/10.1007/s40264-021-01130-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-021-01130-7